Gufic Biosciences Limited — PPTs, 30-05-2025: Investor Presentation

1. Financial Highlights:

Gufic Biosciences reported revenue of Rs 205 Cr in Q4 FY25, up from Rs 196 Cr year-on-year and flat sequentially. EBITDA declined to Rs 27 Cr with a margin of 13.2%, down from 17.2% last quarter and 18.0% a year ago, showing margin pressure. PBT was Rs 10.8 Cr (5.3% margin) and PAT stood at Rs 8.2 Cr, declining compared to last year’s 10.3% margin. Full-year revenue increased to Rs 823 Cr from Rs 809 Cr, with EBITDA at Rs 139 Cr (16.9% margin) and PAT at Rs 70 Cr (8.5% margin). The balance sheet highlights Rs 601 Cr equity, Rs 310 Cr borrowings, and Rs 475 Cr in fixed assets. Working capital remains elevated with inventory of Rs 217 Cr and trade receivables at Rs 315 Cr.

2. Strategic Initiatives & Growth Drivers:

Gufic is strengthening its hospital-based antimicrobials portfolio with new launches like Eclinand IVIG and Sparsh contrast media. Ferticare division aims to grow via clinical trials and new leadership in reproductive tech. Aesthaderm and NeuroCare are expanding through wider practitioner adoption and products like Stunnox toxin. Indore manufacturing ramp-up targets EBITDA break-even in FY26 and margin expansion thereafter. R&D is progressing on dual chamber syringes and immuno-oncology drug SVX-3001.

3. Business Developments:

The company merged Spark and Stellar specialty units into the Zenova division to boost efficiency. Key partnerships include technology transfers and licensing in toxins, infertility, and dermatology. Internationally, Gufic secured a LATAM distribution deal across 17 countries and expanded approvals in Southeast Asia. Market education and clinical data support product adoption.

4. Market Position & Competitive Advantage:

Gufic holds leadership in hospital antimicrobials with top brands like Cavim (Ceftazidime+Avibactam). It is one of India’s largest lyophilized injection makers, reaching 120,000+ doctors and 110,000+ retail outlets. Its strong field force (~1,000+) and extensive CMO network add scale. Differentiation comes from proprietary formulations (botulinum toxin, peptides) and growing global compliance.

5. Investor Implications:

Growth potential looks positive, driven by specialty segment expansion, international footprint, and Indore capacity scale-up. Margin pressure in Q4 likely stems from ramp-up costs and is expected to ease by FY27. Execution risks remain in regulatory approvals and new product adoption. A diversified pipeline in biologics and critical care, plus robust R&D, positions Gufic for a sustained growth run in the medium-to-long term.